Recombinant Human CD367/CLEC4A Protein, C-His (PX-P6237)
概述
图片
参考文献
概述
货号
PX-P6237
品牌
ProteoGenix
描述
Recombinant Human CD367/CLEC4A Protein, C-His (PX-P6237) expressed in Mammalian Cells, Purity: >90% as determined by SDS-PAGE..
Highlights
High Purity (>90% as determined by SDS-PAGE.) — Verified by SDS-PAGE for downstream accuracy.
Mammalian Cells Expression — Optimized for functional studies.
表达系统
Mammalian Cells
Accession号
Q9UMR7
蛋白长度
Gln70-Leu237
应用
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
种属
Homo sapiens (Human)
性质
Recombinant
内毒素水平
Please contact with the lab for this information.
纯度
>90% as determined by SDS-PAGE.
预测分子量
23.05 kDa
状态
Lyophilized
保存溶液
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
重悬
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
运输
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
稳定性和存储
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
别名
C-type lectin DDB27, CLECSF6, CLEC4A, LLIR, CD367, Lectin-like immunoreceptor, DCIR, C-type lectin domain family 4 member A, Dendritic cell immunoreceptor, C-type lectin superfamily member 6
背景
C-type lectin domain family 4 member A (CD367/CLEC4A) is a ~27 kDa protein. C-type lectin receptor that binds carbohydrates mannose and fucose but also weakly interacts with N-acetylglucosamine (GlcNAc) in a Ca(2+)-dependent manner. Involved in regulating immune reactivity. Once triggered by antigen, it is internalized by clathrin-dependent endocytosis and delivers its antigenic cargo into the antigen presentation pathway resulting in cross-priming of CD8(+) T cells. This cross-presentation and cross-priming are enhanced by TLR7 and TLR8 agonists with increased expansion of the CD8(+) T cells, high production of IFNG and TNF with reduced levels of IL4, IL5 and IL13. In plasmacytoid dendritic cells, inhibits TLR9-mediated IFNA and TNF production.
1. Nagae, M. et al. (2016) FEBS letters 590, 1280-8. PMID: 27015765
2. Bates, EE. et al. (1999) Journal of immunology (Baltimore, Md. : 1950) 163, 1973-83. PMID: 10438934
3. Meyer-Wentrup, F. et al. (2008) Blood 111, 4245-53. PMID: 18258799
4. Klechevsky, E. et al. (2010) Blood 116, 1685-97. PMID: 20530286
